Clinical Trial Update: Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ABP 692 against Ocrevus (ocrelizumab) for relapsing-remitting multiple sclerosis (RRMS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• ABP 692 (ocrelizumab)
• Ocrevus (ocrelizumab)

Snippet

Sponsor: Amgen | Conditions: Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Status: ACTIVE_NOT_RECRUITING